Quantcast

Latest Dirucotide Stories

2009-03-02 16:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009. On March 18, 2008, BioMS Medical's Board of Directors passed a...

2009-02-05 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO & Investor Conference in New York. WHEN: Monday February 9th at 2:45pm (Eastern Time) WHERE: Waldorf-Astoria, New York City About BIO CEO & Investor Conference...

2008-12-11 16:30:00

Toronto Stock Exchange Symbol: MS EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Company was the recipient of the "Licensing Deal of the Year Award" at the 4th Annual Scrip Awards held in London, U.K. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide rights to dirucotide, for the treatment of...

2008-12-11 05:30:00

NEW YORK, Dec. 11 /PRNewswire-FirstCall/ -- -- Innovation and Patient-Centered Approach Expected to Drive Future Success -- Lilly Climbs into Top 10 Pharmaceutical Companies in Worldwide Sales and Is Fastest Growing in U.S. -- FIPNet Strategy Expands Global Reach and Improves R&D Productivity -- Company Aims to Reduce Cost of Bringing New Medicine to Market from $1.2 Billion to $800 Million by 2010. -- R&D Pipeline Boasts Unprecedented 59...

2008-09-18 18:00:19

SAN DIEGO, Sept. 18, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that data from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis (MS) was presented today in two poster presentations at the World Congress for Treatment and Research in MS being...

2008-09-05 03:00:28

BioMS Medical, a biotechnology company involved in the treatment of multiple sclerosis, has announced that the FDA has granted fast track designation for the company's lead drug, dirucotide, for the treatment of secondary progressive multiple sclerosis. Dirucotide (MBP8298) is currently being evaluated in a US pivotal Phase III trial, named Maestro-03, at 68 sites with approximately 510 patients. Kevin Giese, president and CEO of BioMS Medical, said: "Our receipt of fast track designation...

2008-09-04 09:00:48

EDMONTON, Sept. 4 /PRNewswire-FirstCall/ -- BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately...

2008-08-13 18:00:43

EDMONTON, Aug. 13 /PRNewswire-FirstCall/ -- BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and European study of dirucotide (MBP8298) in patients with secondary progressive...

2008-08-12 18:00:29

EDMONTON, Aug. 12 /PRNewswire-FirstCall/ -- BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing MBP8298 (dirucotide), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US. "The three randomized late-stage clinical trials for MBP8298...

2008-08-01 09:01:04

EDMONTON, Aug. 1 /PRNewswire-FirstCall/ -- BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, and is being conducted at 68 trial sites in the U.S. "We have had great success in recruiting patients into the trial,...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related